# Dinalbuphine Ester (Naldebain) for Pain Management After Cesarean Section

> **NCT06344169** · PHASE2,PHASE3 · RECRUITING · sponsor: **Dalin Tzu Chi General Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Postsurgical Pain
- Cesarean Section
- Chronic Post-surgical Pain

## Interventions

- **DRUG:** Sebacoyl Dinalbuphine Ester
- **DRUG:** Morphine

## Key facts

- **NCT ID:** NCT06344169
- **Lead sponsor:** Dalin Tzu Chi General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-06
- **Primary completion:** 2026-03-14
- **Final completion:** 2026-06-14
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06344169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06344169, "Dinalbuphine Ester (Naldebain) for Pain Management After Cesarean Section". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06344169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*